期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

正确认识他汀类药物的临床疗效和安全性 被引量：1

下载PDF
导出
摘要 他汀类药物又称HMG-CoA还原酶抑制剂。首个品种洛伐他汀（lovastatin）于1987年9月1日获美国食品药品监督管理局（FDA）批准上市。
作者 曲静伟 洪中立
机构地区 宁波大学医学院附属医院
出处 《现代实用医学》 2010年第4期473-476,共4页 Modern Practical Medicine
关键词 他汀类药物 HMG-COA还原酶抑制剂 临床疗效 美国食品药品监督管理局 安全性 批准上市 洛伐他汀
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献347

同被引文献5

  • 1甘润韬,李为民,李竹琴,王岚峰.超敏C反应蛋白及血脂水平与急性冠状动脉综合征患者6个月内预后的关系[J].临床心血管病杂志,2006,22(11):650-652. 被引量：6
  • 2Crisby M, Nordin - Fredriksson G, Shah PK, et al. Pravas- tatin treatment increases collagen content and decreases lipid content, inflammation, metalloprotelnases, and cell death in human carotid plaques: implications for plaque stalilization[J], Circulation, 2001, 103(7):226.
  • 3Wright R S, Andermn J L, Adams C D, et al. American Col- lege of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patientswith Unstable Angina/Non - ST -Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons[J], J Am (2011 Cardiol, 2011, 57(19) : e215.
  • 4王显.急性冠脉综合征与动脉粥样硬化“络风内动”假说[J].中国医院用药评价与分析,2011,11(9):771-773. 被引量：20
  • 5赵晓燕,李泉生.血浆C反应蛋白与不稳定型心绞痛危险度分级关系的探讨[J].临床心血管病杂志,2003,19(5):277-279. 被引量：22

引证文献1

二级引证文献13

现代实用医学
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部